Vertex’s second-generation diabetes cell therapy fails early-stage study
Vertex Pharmaceuticals announced Friday afternoon that it won’t move forward with its type 1 diabetes cell therapy that’s delivered in a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
